stockmarketproxy
/
UTHRNasdaq SEC EDGAR

UNITED THERAPEUTICS Corp

Pharmaceutical Preparations·SILVER SPRING, MD·FY end 12/31·CIK 1082554
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$3.2B$2.9B$2.3B$1.9B$1.7B
Gross Profit$2.8B$2.6B$2.1B$1.8B$1.6B
Operating Income$1.5B$1.4B$1.2B$979.7M$555.9M
Net Income$1.3B$1.2B$984.8M——
Operating CF$1.6B$1.3B$978.0M$802.5M$598.2M
Capex$520.5M$246.5M$230.4M$138.8M$120.8M
Free Cash Flow$1.0B$1.1B$747.6M$663.7M$477.4M
Buybacks$1.0B$1.0B———
Dividends——————
Gross Margin87.9%89.2%88.9%92.2%92.7%
Operating Margin46.9%47.9%50.9%50.6%33.0%
Net Margin41.9%41.5%42.3%——
FCF Margin32.7%37.6%32.1%34.3%28.3%
R&D / Revenue17.3%16.7%17.5%16.7%32.0%
Effective Tax22.1%22.3%22.7%23.5%19.9%
Debt / Equity——————
Buybacks / FCF96.1%92.5%———

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
UTHR
76:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
UTHR
$0M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
UTHR
41.9%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%